• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Gene therapy for hepatocellular carcinoma using an endogenous antineoangiogenetic factor, angiostatin

Research Project

Project/Area Number 11670513
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Gastroenterology
Research InstitutionNagasaki University

Principal Investigator

NAKATA Keisuke  School of Medicine, Nagasaki University, Associated Professor, 医学部, 助教授 (40217740)

Co-Investigator(Kenkyū-buntansha) NAKAO Kazuhiko  Health Research Center, Nagasaki University Lecturer, 保健管理センター, 講師 (00264218)
Project Period (FY) 1999 – 2000
Project Status Completed (Fiscal Year 2000)
Budget Amount *help
¥3,200,000 (Direct Cost: ¥3,200,000)
Fiscal Year 2000: ¥1,200,000 (Direct Cost: ¥1,200,000)
Fiscal Year 1999: ¥2,000,000 (Direct Cost: ¥2,000,000)
KeywordsHepatoma / Gene therapy / Angiostatin / Anti-neoantigogenesis / α-Fetoprotein / Adenovines vector / 肝癌培養細胞
Research Abstract

Hepatocellular carcinoma (HCC) is characterized with a hypervascular tumor. Therefore, transcatheter arterial embolization is a major treatment modality for human HCC, but its efficacy is not yet satisfactory. In the present study, the inhibitory effects of a potent endogenous anti-neoangiogenetic factor, angiostatin, on growth and metastatic potentials of HCC were evaluated by means of angiostatin gene transfection into human hepatoma cell lines. Human plasminogen cDNA was isolated from Hep G2 human hepatoma cells, and the fragment corresponding to the kringle domains 1 to 4 was linked to a secretory signal sequence (SS) and preactivation peptide (PA), and cloned into adenovirus vector (AV-S-K1-4). HuH7 and HepG2 human hepatoma cell lines were co-transfected with the angiostatin gene expression plasmid and the neomycinresistance gene plasmid, and the cells were selected by G418 serection for 3 weeks. However, the stable transfectants expressing sufficient levels of angiostatin could not be established. In contrast, when HuH7 and HepG2 cells were infected with AV-S-K1-4, large amounts of angiostatin were expressed in both cell lines. Cell growth in AV-S-K1-4-infected cells was almost similar to that in the parental cells, while, in a double chamber model, AV-S-K1-4-infected cells clearly suppressed cell proliferation of bovine capillary endothelial cells, although apoptosis of the endothelial cells could not be identified. In animal experiments, parental HuH7 cells were inoculated subcutaneously in athymic mice. Two weeks later AV-S-K1-4 or a control adenovirus vector were directly injected into the subcutaneous tumor. Tumor growth in mice injected with AV-S-K1-4 was apparently suppressed, compared with that in mice receiving a vehicle treatment. These results suggest that gene therapy with angiostatin gene transfection into hepatoma cells inhibits tumor growth probably through blocking tumor angiogenesis.

Report

(3 results)
  • 2000 Annual Research Report   Final Research Report Summary
  • 1999 Annual Research Report
  • Research Products

    (17 results)

All Other

All Publications (17 results)

  • [Publications] Hiroki Ishikawa: "Utilization of variant-type of human α-fetoprotein promoter in gene therapy targeting for hepatocellular carcinoma"Gene Therapy. 6. 465-470 (1999)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Hiroki Ishikawa: "Differential regulation of albumin gene expression by heparin-binding epidermal growth factor-like growth factor in α-fetoprotein-producing and-nonproducing human hepatoma cells"Tumor Biology. 20. 130-138 (1999)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Hiroyuki Mazume: "Effect of simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on α-fetoprotein gene expression through interaction with the ras-mediated pathway"Journal of Hepatology. 30. 904-910 (1999)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Yuka Shima: "Activation of caspase-8 in transforming growth factor-β-induced apoptosis of human hepatoma cells"Hepatology. 33. 1215-1222 (1999)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] 中田恵輔: "肝癌の遺伝子治療"生物物理化学. 44. 109-113 (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] H Ishikawa, K Nakata, F Mawatari, T Ueki, S Tsuruta, A Ido, K Nakao, Y Kato, N Ishii, K Eguchi: "Utilization of variant-type of human α-fetoprotein promoter in gene therapy targeting for hepatocellular caricinoma."Gene Ther. 6. 465-470 (1999)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] H Ishikawa, K Nakata, S Tsuruta, K Nakao, Y Kato, T Tamaoki, K Eguchi: "Differential regulation of albumin gene expression by heparin-binding epidermal growth factor-like growth factor in α-fetoprotein-producing and-nonproducing human hepatoma cells."Tumor Biol. 20, 4. 130-138 (1999)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] H Mazume, K Nakata, D Hida, K Hamasaki, S Tsuruta, K Nakao Y Kato, K Eguchi: "Effect of simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on α-fetoprotein gene expression through interaction with the ras-mediated pathway."J Hepatol. 30, 5. 904-910 (1999)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Y Shima, K Nakao, T Nakashima, A Kawakami, K Nakata, K Hamasaki, Y Kato, K Eguchi, N Ishii: "Activation of caspase-8 in transforming growth factor-β-induced apoptosis of hepatoma cells."Hepatology. 30. 1215-1222 (1999)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] K Nakata, K Nakao, K Eguchi: "Gene therapy for hepatocellular carcinoma."Jpn J Electroph. 44. 109-113 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Hiroki Ishikawa: "Utilization of variant-type of human α-fetoprotein promoter in gene therapy targeting for hepatocellular carcinoma"Gene Therapy. 6. 465-470 (1999)

    • Related Report
      2000 Annual Research Report
  • [Publications] Hiroki Ishikawa: "Differential regulation of albumin gene expression by heparin-binding bpidermal growth Factor-like growth factor in α-fetoprotein-producing and-nonproducing human hepatoma cells"Tumor Biology. 20. 130-138 (1999)

    • Related Report
      2000 Annual Research Report
  • [Publications] Hiroyuki Mazume: "Effect of simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on α-fetoprotein gene expression through interaction with the ras-mediated pathway"Journal of Hepatology. 30. 904-910 (1999)

    • Related Report
      2000 Annual Research Report
  • [Publications] Yuka Shima: "Activation of caspase-8 in transforming growth factor-β-induced apoptosis of human hepatoma cells"Hepatology. 30. 1215-1222 (1999)

    • Related Report
      2000 Annual Research Report
  • [Publications] 中田恵輔: "肝癌の遺伝子治療"生物物理科学. 44. 109-113 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] Hiroki Ishikawa: "Utilization of variant-type of human α-fetoprotein promoter in gene therapy targeting for hepato cellular carcinoma"Gene Therapy. 6. 465-470 (1999)

    • Related Report
      1999 Annual Research Report
  • [Publications] 中田恵輔: "肝臓の遺伝子治療"生物物理化学. (in press). (2000)

    • Related Report
      1999 Annual Research Report

URL: 

Published: 1999-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi